Women Ages 35 to 60 Face Higher Cancer Mortality Than Men Across 20 Countries

JAMA Network

Women live longer than men. That is one of the most consistent findings in demography, holding across virtually all countries and time periods. But within that broad advantage lies an uncomfortable exception: in the middle decades of life, between ages 35 and 60, women in wealthy countries die of cancer at higher rates than men.

A new population-level study confirms that this gap is not a statistical quirk or artifact of a single country's data. It is a persistent, cross-national pattern that has endured across birth cohorts and calendar time.

Twenty countries, one consistent pattern

The study, published in JAMA Network Open and led by Vladimir Canudas-Romo at the Australian National University, examined cancer mortality data from 20 low-mortality countries. The focus was on the 35-to-60 age range, a period when cancer strikes at what many would consider the prime of working and family life.

Across all 20 countries, the finding was consistent: women in this age bracket experienced a cancer mortality disadvantage compared to men. This pattern held when the researchers looked across different birth cohorts and over time, suggesting it is not a generational anomaly or a product of changing diagnostic practices.

The driver, the researchers conclude, is early-onset female reproductive cancers, including breast cancer and cervical cancer. These cancers strike women in their 30s, 40s, and 50s at rates that have no male equivalent in the same age range. While men's cancer mortality in this period is spread across several organ systems, women face concentrated risk from a specific category of disease.

Why this matters beyond the numbers

The finding challenges a common assumption in public health messaging: that women's overall survival advantage means they are generally healthier than men at every age. In the middle decades, the opposite is true for cancer. This has direct implications for screening programs, research funding allocation, and clinical attention.

Breast cancer screening, typically beginning at age 40 or 50 depending on the country, catches many cases. But the persistence of the mortality gap across time and birth cohorts suggests that current prevention and early detection strategies have not fully closed it. Cervical cancer, while increasingly preventable through HPV vaccination, continues to contribute to mortality in cohorts that were too old for vaccination when it became available.

The researchers argue that these findings underscore the ongoing need for action on three fronts: prevention of early-onset reproductive cancers, improved early detection, and better treatment options for women diagnosed in mid-life.

What drives the persistence?

Several factors may contribute to the gap's stubbornness. Breast cancer incidence has been rising in many countries among younger women, a trend whose causes are actively debated but may involve changing reproductive patterns, obesity rates, and environmental exposures. Treatment advances have improved breast cancer survival significantly, but they have not eliminated mortality, particularly for aggressive subtypes like triple-negative breast cancer that disproportionately affect younger women.

The cross-national consistency of the finding also suggests that the gap is not primarily driven by differences in healthcare systems. Countries with universal healthcare and strong screening programs show the same pattern as those with more fragmented systems. This points to biological and epidemiological factors that transcend healthcare delivery.

Limitations of a population-level view

The study works at the population level, comparing overall cancer mortality rates between sexes across countries and birth cohorts. It does not drill into specific cancer types, treatment patterns, or individual risk factors. The "female reproductive cancer" explanation is inferred from the age pattern and known epidemiology rather than directly decomposed in this particular analysis.

Population-level studies also cannot account for changes in cancer classification, death certificate coding practices, or diagnostic intensity that may differ between countries and over time. And the restriction to 20 low-mortality countries means the findings may not generalize to low- and middle-income settings, where cancer mortality patterns differ substantially due to different disease burdens, screening availability, and healthcare infrastructure.

The study also cannot determine whether the gap is narrowing or widening in the most recent data, a question that would require more granular analysis of recent trends.

The case for age-specific cancer strategies

Cancer research and policy often operate in cancer-type silos: breast cancer programs, lung cancer programs, colorectal cancer programs. This study makes a case for thinking in age-and-sex-specific terms as well. Women in their 30s, 40s, and 50s face a distinct cancer mortality burden that differs qualitatively from what men in the same age bracket experience and from what women face at older ages.

Addressing that burden may require not just better screening and treatment for individual cancer types, but a coordinated approach that recognizes the concentrated vulnerability of women in mid-life to reproductive cancers as a public health priority in its own right.